Case Study Revisited

Our 70-year-old patient presents with Stage D severe, chronic degenerative MR. She has a class I indication for mitral valve repair. Although evidence is promising, it remains limited and surgical repair should be offered first to our patient. However, she would likely fall in the high-risk stratification of MR repair patients and may refuse surgical intervention. Analysis of her anatomy should be performed and she should be medically optimized. If she is deemed high risk and her anatomy is favorable, it would be reasonable to refer her to a Valve Center of Excellence experienced in the MitraClip therapy for percutaneous repair.

Conclusions

Mitral regurgitation is a common valvular disorder with a well-described, progressive morbidity and mortality. Surgical repair has delivered significantly improved outcomes; however, many patients with MR, particularly with an aging population with increasing MR prevalence, are poor surgical candidates. Transcatheter MV repair, as described above with the MitraClip, has shown significant promise in delivering similar outcomes with a satisfactory safety profile. Although currently only approved by the FDA for stage D degenerative MR repair in the United States, observational studies in Europe have shown similar levels of evidence with percutaneous repair of functional MR, including cases with advanced or refractory HF. Consequently, indications may soon expand with further long-term and expanded-use studies.


Continue Reading

References

  1. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897-902. 
  2. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009;373:1382-1394.
  3. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
  4. Ahmed MI, McGiffin DC, O’Rourke RA, Dell’Italia LJ. Mitral regurgitation. Curr Prob Cardiol. 2009;34:93-136.
  5. Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. Circulation. 1995;91:1022-1028.
  6. Wan B, Rahnavardi, Tian DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg. 2013;2:683-692.
  7. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on valvular heart disease. Eur Heart J. 2003;24:1231-1243.
  8. Shuhaiber J, Anderson RJ. Meta-analysis of clinical outcomes following surgical mitral valve repair or replacement. Eur J Cardiothorac Surg. 2007;31:267-275.
  9. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395-1406.
  10. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary. Circulation 2014;129:2440-2492.
  11. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiology 2014;64:182-192.
  12. Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28:1358-1365.
  13. Chiam PTL, Ruiz CE. Percutaneous transcatheter mitral valve repair: a classification of the technology. JACC Cardiovasc Interven. 2011;4(1):1-13.
  14. Boekstegers P, Hausleiter J, Baldus S, et al. Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol. 2014;103:85-96.
  15. Vahanian, A, Uung B. The new ESC/EACTS guidelines on the management of valvular heart disease. Arch Cardiovasc Dis. 2012;105:465-467.
  16. Alfieri O, De Bonis M. The role of the edge-to-edge repair in the surgical treatment of mitral regurgitation. J Cardiac Surg. 2010;25(5):536-541.
  17. Vakil K, Roukoz H, Sarraf M, et al. Safety and efficacy of the MitraClip system for severe mitral regurgitation: a systematic review. Cath Cardiovasc Interven. 2014;84:129-136.
  18. Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST phase I clinical trial. J Am Coll Cardiol. 2005;46:2134-2140.
  19. Mauri L, Foster E, Glower DD, et al. 4-Year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll  Cardiol. 2013;62:317-328.
  20. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll  Cardiol. 2013;62:1052-1061.
  21. Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012;14(9):1050-1055.
  22. Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012; 59:130-139.
  23. Philip F, Athappan G, Tuzcu EM, et al. MitraClip for severe symptomatic mitral regurgitation in patients at high surgical risk: a comprehensive systematic review. Cath Cardiovasc Interven. 2014;84:581-590.
  24. D’ascenzo F, Moretti C, Marra WG, et al. Meta-analysis of the usefulness of MitraClip in patients with functional mitral regurgitation. Am  Cardiol. 2015;116:325-331.
  25. Detaint D, Sundt TM, Nkomo VT, et al. Surgical correction of mitral regurgitation in the elderly: outcomes and recent improvements. Circulation. 2006;114:265-272.
  26. Auricchio A, Schillinger W, Meyer S, et al. Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip® improves symptoms and promotes reverse remodeling. J Am Coll  Cardiol.  2011;58:2183-2218.
  27. Franzen O, van der Heyden J, Schluter M et al. MitraClip® therapy in patients with end-stage systolic heart failure. Eur J Heart Fail. 2011;13:569-576.
  28. Grayburn PA, Foster E, Sangli C et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation 2013;128:1667-1674.
  29. Munkholm-Larsen S, Wan B, Tian DH, et al. A systematic review on the safety and efficacy of percutaneous edge-to-edge mitral valve repair with the MitraClip system. Heart. 2013;100:473-478.
  30. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352:875-883.
  31. Paranskaya L, D’Ancona G, Bozdag-Turan I, et al. Percutaneous vs surgical repair of mitral valve regurgitation: single institution early and midterm outcomes. Can J Cardiol. 2013;29:452-459.